Table 2. Baseline, three-month, and six-month patient reported outcomes.
| Variable | Morphine (n=98) | Fentanyl (n=61) | Hydromorphone (n=71) | P value |
|---|---|---|---|---|
| Baseline patient reported outcomes measures | ||||
| ODI | 47.16±2.55 | 45.00±3.20 | 50.16±3.16 | 0.5152 |
| VAS-NP | 2.74±1.35 | 5.68±2.18 | 6.71±1.75 | 0.1750 |
| VAS-LP | 4.09±0.70 | 2.67±1.19 | 3.88±1.00 | 0.5845 |
| VAS-BP | 4.56±0.69 | 5.17±1.15 | 5.83±0.94 | 0.5484 |
| SF-36 PCS | 28.07±1.09 | 28.64±1.33 | 26.00±1.30 | 0.3192 |
| SF-36 MCS | 45.14±1.72 | 43.21±2.11 | 41.20±2.10 | 0.3496 |
| Three-month patient reported outcomes measures | ||||
| ODI | 35.51±2.68 | 35.47±3.47 | 43.42±3.23 | 0.1281 |
| VAS-NP | 2.95±1.71 | 5.60±2.11 | 3.34±2.36 | 0.6058 |
| VAS-LP | 1.59±0.58 | 1.00±0.79 | 0.36±0.82 | 0.4746 |
| VAS-BP | 3.23±0.68 | 1.19±0.90 | 4.33±0.93 | 0.0545 |
| SF-36 PCS | 31.44±1.52 | 32.65±1.85 | 28.75±1.79 | 0.2974 |
| SF-36 MCS | 44.50±1.88 | 49.87±2.38 | 42.42±2.26 | 0.0691 |
| Six-month patient reported outcomes measures | ||||
| ODI | 37.07±3.12 | 40.09±4.37 | 39.17±3.80 | 0.8305 |
| VAS-NP | 6.84±13.90 | 4.42±3.63 | 3.88±3.31 | 0.7388 |
| VAS-LP | 1.11±0.69 | 1.22±0.98 | 3.09±0.89 | 0.1952 |
| VAS-BP | 1.78±0.76 | 2.67±1.07 | 3.00±0.97 | 0.5811 |
| SF-36 PCS | 33.17±1.50 | 31.80±2.12 | 29.84±1.85 | 0.3812 |
| SF-36 MCS | 43.85±2.23 | 45.20±3.09 | 42.84±2.75 | 0.8496 |
ODI, Oswestry Disability Index; VAS-NP, Neck-Pain Visual Analog Scale; VAS-BP, Back-Pain Visual Analog Scale; VAS-LP, Leg-Pain Visual Analog Scale; PCS, physical component score; MCS, mental component score.